/VIMIAN.ST

VIMIAN.ST Stock - Vimian Group AB (publ)

Q: What is the analyst price target for VIMIAN.ST?

Analyst price target information is not currently available for VIMIAN.ST.

Q: What is VIMIAN.ST's market cap?

Market capitalization information is not currently available for VIMIAN.ST.

Healthcare|Medical - Diagnostics & Research|STO

$29.58+0.14%

+$0.04 (+0.14%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $32.54

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VIMIAN.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.51

52W High$47.30

52W Low$27.80

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$374.80M	$331.73M	$281.31M	$173.35M	$137.75M
Gross Profit	$258.30M	$229.43M	$193.99M	$122.85M	$95.52M
Gross Margin	68.9%	69.2%	69.0%	70.9%	69.3%
Operating Income	$49.20M	$41.27M	$39.36M	$21.60M	$74.80M
Net Income	$18.50M	$9.84M	$-7,198,000	$6.59M	$52.79M
Net Margin	4.9%	3.0%	-2.6%	3.8%	38.3%
EPS	$0.04	$0.02	$-0.02	$0.02	$0.14

Company Overview

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Visit Website

Earnings History & Surprises

VIMIAN.ST

Beat Rate

21%

Last 14 quarters

Avg Surprise

-53.1%

EPS vs Estimate

Beats / Misses

3/11

Last 12 quarters

Latest EPS

$0.14

Q4 2025

EPS Surprise History

Q4 23

-241.3%

$-0.15vs$0.10

Q1 24

-70.2%

$0.09vs$0.30

Q2 24

-54.4%

$0.11vs$0.24

Q3 24

-119.4%

$-0.05vs$0.24

Q4 24

-4.0%

$0.27vs$0.28

Q1 25

-60.0%

$0.09vs$0.23

Q2 25

-38.4%

$0.18vs$0.29

Q4 25

-41.8%

$0.14vs$0.23

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Oct 22, 2025	$0.23	$0.14	-41.8%	✗ MISS
Q2 2025	Jun 30, 2025	$0.29	$0.18	-38.4%	✗ MISS
Q1 2025	Mar 31, 2025	$0.23	$0.09	-60.0%	✗ MISS
Q4 2024	Dec 31, 2024	$0.28	$0.27	-4.0%	✗ MISS
Q3 2024	Sep 30, 2024	$0.24	$-0.05	-119.4%	✗ MISS
Q2 2024	Jun 30, 2024	$0.24	$0.11	-54.4%	✗ MISS
Q1 2024	Mar 31, 2024	$0.30	$0.09	-70.2%	✗ MISS
Q4 2023	Dec 31, 2023	$0.10	$-0.15	-241.3%	✗ MISS
Q3 2023	Sep 30, 2023	$0.15	$0.18	+25.1%	✓ BEAT
Q2 2023	Jun 30, 2023	$0.13	$0.07	-42.2%	✗ MISS
Q1 2023	Mar 31, 2023	$0.29	$0.13	-54.3%	✗ MISS
Q4 2022	Dec 31, 2022	—	$-0.52	—	—
Q3 2022	Sep 30, 2022	$0.13	$-0.04	-134.5%	✗ MISS
Q2 2022	Jun 30, 2022	$0.15	$0.28	+89.4%	✓ BEAT
Q1 2022	Mar 31, 2022	$0.14	$0.14	+2.7%	✓ BEAT
Q4 2021	Dec 31, 2021	—	$0.05	—	—
Q3 2021	Sep 30, 2021	—	$-0.01	—	—
Q2 2021	Jun 30, 2021	—	$-0.10	—	—
Q1 2021	Mar 31, 2021	—	$0.22	—	—
Q4 2020	Dec 31, 2020	—	$1.43	—	—

Frequently Asked Questions about VIMIAN.ST

What is VIMIAN.ST's current stock price?

Vimian Group AB (publ) (VIMIAN.ST) is currently trading at $29.58 per share. The stock has moved +0.14% today.

What is the analyst price target for VIMIAN.ST?

No analyst price targets are currently available for this stock.

What sector is Vimian Group AB (publ) in?

Vimian Group AB (publ) operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the STO exchange.

What is VIMIAN.ST's market cap?

Vimian Group AB (publ) has a market capitalization of $15.56 billion, making it a large-cap company.

Does VIMIAN.ST pay dividends?

No, Vimian Group AB (publ) does not currently pay a dividend to shareholders.